0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Preventing Fungal Infection in Neutropenic Patients with Acute Leukemia: Fluconazole Compared with Oral Amphotericin B

Francesco Menichetti, MD; Albano Del Favero, MD; Piero Martino, MD; Giampaolo Bucaneve, MD; Alessandra Micozzi, MD; Domenico D'Antonio, MD; Paolo Ricci, MD; Mario Carotenuto, MD; Vincenzo Liso, MD; Anna Maria Nosari, MD; Tiziano Barbui, MD; Giampiero Fasola, MD; Franco Mandelli, MD, The GIMEMA Infection Program*
[+] Article and Author Information

From Istituto di Malattie Infettive and Istituto di Clinica Medica 1, Universita di Perugia; Istituto di Ematologia, Universita “La Sapienza” Roma; Divisione di Ematologia, Ospedale Pescara; Istituto di Ematologia, Universita di Bologna; Divisione di Ematologia, Ospedale S. Giovanni Rotondo; Istituto di Ematologia, Universita di Bari; Divisione Talamona, Ospedale Niguarda, Milano; Divisione di Ematologia, Ospedale di Bergamo; Cattedra di Ematologia, Ospedale di Udine. Requests for Reprints: Francesco Menichetti, MD, Istituto di Malattie Infettive, Universita di Perugia, Ospedale Policlinico Monteluce, 06122 Perugia, Italy. Grant Support: By grants from Pfizer, Italy; and by contract N. 92.02177.39/115.19159 with Consiglio Nazionale delle Ricerche.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1994;120(11):913-918. doi:10.7326/0003-4819-120-11-199406010-00003
Text Size: A A A

Objective: To compare the efficacy and tolerability of fluconazole and oral amphotericin B in preventing fungal infection in neutropenic patients with acute leukemia.

Design: A randomized, controlled, multicenter trial.

Setting: 30 hematologic units in tertiary care or university hospitals.

Patients: 820 consecutive, afebrile, adult patients with acute leukemia and chemotherapy-induced neutropenia.

Intervention: Patients were randomly assigned to receive fluconazole, 150 mg, as a once-daily capsule, or amphotericin B suspension, 500 mg every 6 hours.

Measurements: An intention-to-treat analysis was done for 820 patients: 420 treated with fluconazole and 400 treated with oral amphotericin B.

Results: Definite systemic fungal infection occurred in 2.6% of fluconazole recipients and 2.5% of amphotericin B recipients; suspected systemic fungal infection requiring the empiric use of intravenous amphotericin B occurred in 16% of fluconazole recipients and 21% of oral amphotericin B recipients, a difference of 5 percentage points (95% CI for difference, −0.02% to 10%; P = 0.07). Superficial fungal infection was documented in 1.7% of fluconazole recipients compared with 2.7% of amphotericin B recipients, a difference of one percentage point (CI of difference, −0.9% to 3%; P > 0.2). The distribution of fungal isolates in systemic and superficial fungal infection was similar in both groups. The overall mortality rate accounted for 10% in both groups. An excellent compliance was documented for 90% of patients treated with fluconazole compared with 72% of those treated with amphotericin B suspension, a difference of 18 percentage points (CI for difference, 13% to 23%). Side effects were documented less frequently in fluconazole than in amphotericin B recipients (1.4% compared with 7%, a difference of 5.6 percentage points; CI for difference, 2% to 8%; P < 0.01).

Conclusion: Fluconazole was at least as effective as oral amphotericin B in preventing systemic and superficial fungal infection and the empiric use of amphotericin B in neutropenic patients with acute leukemia but was better tolerated.

*Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. See Appendix for additional investigators in the study and end of text for participating institutions and current author addresses.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)